|
 |
|
|
|
| |
|
|
|
|
| Table 14. HIV-infected patients receiving a Tuberculin Skin Test (TST) by data source and sex |
|
|
|
|
View PDF
|
|
Data in Tables 14-15 are based on the following analyses:
- Proportion of patients in SHDC receiving a TST before or during 1998.
- Among patients interviewed in SHAS in 1999, proportion with no prior history of TB and no prior positive TST who received a TST.
- Among newly diagnosed HIV/AIDS patients in MOPTB ever receiving a TST after HIV diagnosis.
|
 |
|
|
|
|
|
|
|
|
| Data Source |
Total |
|
Male |
|
Female |
| % |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
| SHDC Site A |
55 |
158/288 |
|
56 |
100/178 |
|
54 |
59/110 |
| SHDC Site B |
62 |
157/253 |
63 |
100/158 |
58 |
55/95 |
| SHDC Site C |
34 |
127/374 |
33 |
85/258 |
37 |
43/116 |
| SHAS |
75 |
1,497/2,002 |
76 |
1,113/1,470 |
72 |
384/532 |
| MOBPTB* |
50 |
437/869 |
51 |
320/629 |
49 |
116/235 |
|
|
|
|
*The MOPTB total contains 5 patients with missing sex. |
- Overall, the proportion of patients receiving a TST varied across studies from 34% to 75%.
- Data collected for patients in SHDC are limited to those receiving a TST from their SHDC provider. Receipt of a TST from a non SHDC provider would not be documented in the patients medical record unless disclosed by the patient and documented by the provider.
- Similar proportions of males and females from all data sources received a TST.
- Differences in the populations represented by the samples at the 3 SHDC sites may account for the difference in receipt of TST (see
Technical Notes). Providers at Sites A and B may provide more HIV-related care and are therefore more likely to provide a TST compared with providers not in or near metropolitan areas at Site C.
- Among the 437 newly diagnosed HIV/AIDS cases in MOPTB, 83% of the tests were performed within 12 months of diagnosis.
|
|
|
|
|
|
|
|
|
|
|
